Werewolf Therapeutics (HOWL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on the stock and has a $4.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Reni Benjamin’s rating is based on several compelling factors that highlight Werewolf Therapeutics as a promising investment. The company has a strong cash position of $111 million, which is expected to sustain operations until the second quarter of 2026. This financial stability, coupled with a strategic partnership with Jazz Pharmaceuticals, enhances its growth prospects.
Furthermore, Werewolf is advancing its clinical pipeline with significant milestones on the horizon. The anticipated data from the WTX-124 expansion in the fourth quarter of 2025, along with ongoing discussions with the FDA for potential accelerated approval, underscore the company’s innovative approach. Additionally, the initiation of the WTX-330 Phase 1/2 study and the development of preclinical candidates targeting inflammatory diseases further bolster its long-term potential.
In another report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $8.00 price target.